| Code | Description | Claims | Beneficiaries | Total Paid |
|---|
| 88175 |
Cytopathology, cervical or vaginal, any reporting system; collected in preservative fluid, automated thin layer |
11,129 |
11,087 |
$245K |
| 87624 |
Infectious agent detection by nucleic acid; human papillomavirus (HPV), high-risk types |
5,862 |
5,854 |
$184K |
| U0003 |
Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r |
2,984 |
1,553 |
$161K |
| 88305 |
Level IV - Surgical pathology, gross and microscopic examination |
1,680 |
1,621 |
$71K |
| 87491 |
Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe |
672 |
669 |
$19K |
| 87591 |
Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe |
662 |
655 |
$19K |
| 88141 |
|
628 |
626 |
$6K |
| 88350 |
|
38 |
26 |
$6K |
| U0005 |
Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 |
1,207 |
515 |
$5K |
| 88313 |
|
39 |
25 |
$2K |
| 88348 |
|
24 |
13 |
$2K |
| 88173 |
|
79 |
78 |
$2K |
| 88346 |
|
39 |
25 |
$898.91 |
| G0145 |
Screening cytopathology, cervical or vaginal (any reporting system), collected in preservative fluid, automated thin layer preparation, with screening by automated system and manual rescreening under physician supervision |
74 |
74 |
$0.00 |